Replies to post #131201 on Biotech Values

[kamehameha]

Look at the slideshow from AASLD for more detail.

here is what the slides say:

2. POSITRON: 225 HCV GT2/3
patients who are interferon intolerant or ineligible
PSI-7977/RBV 12 wks vs. Placebo

3. NEUTRINO: 280 GT1 (& all other genotypes)
patients who are interferon intolerant or ineligible
PSI-7977/RBV 12 wks vs. Placebo

So Neutrino and Positron both will only treat patients that can not tolerate INF. Considering that these are phase III trials chances are high that PSI-7977 on approval will have a restricted label, only for use in patients that can not tolerate INF. That's an impressive reduction in market potential!

but this still does not answer the question, how INF intolerance is determined.